Abstract
Thirty-four evaluable patients were treated with vinorelbine, a novel, semisynthetic vinca alkaloid, as first-line chemotherapy for advanced breast cancer. They received vinorelbine 25 mg m-2 i.v. given weekly for a maximum of 16 cycles. Two patients achieved a complete remission and 15 a partial remission, giving a response rate of 17/34 (50%; 95% CI of 34-66%); median response duration was 5.8 months. The median progression-free interval was 4.4 months and median survival 9.9 months. Treatment was generally well tolerated. Fatigue was the most common side-effect. The main reason for dose adjustments was myelosuppression; 68% of patients had WHO grade 3 or 4 neutropenia and there was one death attributed to neutropenic sepsis. Nausea/vomiting and neuropathy were mild and alopecia was uncommon. This study confirms vinorelbine as a highly active, well-tolerated agent in advanced breast cancer worthy of evaluation in combination chemotherapy regimens.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Canobbio L., Boccardo F., Pastorino G., Brema F., Martini C., Resasco M., Santi L. Phase-II study of Navelbine in advanced breast cancer. Semin Oncol. 1989 Apr;16(2 Suppl 4):33–36. [PubMed] [Google Scholar]
- Cros S., Wright M., Morimoto M., Lataste H., Couzinier J. P., Krikorian A. Experimental antitumor activity of Navelbine. Semin Oncol. 1989 Apr;16(2 Suppl 4):15–20. [PubMed] [Google Scholar]
- Cros S., Wright M., Morimoto M., Lataste H., Couzinier J. P., Krikorian A. Experimental antitumor activity of Navelbine. Semin Oncol. 1989 Apr;16(2 Suppl 4):15–20. [PubMed] [Google Scholar]
- Fumoleau P., Delgado F. M., Delozier T., Monnier A., Gil Delgado M. A., Kerbrat P., Garcia-Giralt E., Keiling R., Namer M., Closon M. T. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 1993 Jul;11(7):1245–1252. doi: 10.1200/JCO.1993.11.7.1245. [DOI] [PubMed] [Google Scholar]
- Mathé G., Reizenstein P. Phase I pharmacologic study of a new Vinca alkaloid: navelbine. Cancer Lett. 1985 Jul;27(3):285–293. doi: 10.1016/0304-3835(85)90186-7. [DOI] [PubMed] [Google Scholar]
- Romero A., Rabinovich M. G., Vallejo C. T., Perez J. E., Rodriguez R., Cuevas M. A., Machiavelli M., Lacava J. A., Langhi M., Romero Acuña L. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol. 1994 Feb;12(2):336–341. doi: 10.1200/JCO.1994.12.2.336. [DOI] [PubMed] [Google Scholar]